Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Bolivian hemorrhagic fever (BHF), caused by the Machupo virus (MACV), is a severe acute viral hemorrhagic fever characterized by fever, myalgia, and arthralgia followed by hemorrhagic and neurological manifestations.
Biomarker and diagnostic research for Bolivian hemorrhagic fever has been reported in the published literature.
No clinical trials have been registered for Bolivian hemorrhagic fever.
52 publications have been identified in PubMed for Bolivian hemorrhagic fever. Research spans Basic Science / Preclinical (33%), Epidemiology / Natural History (21%), and Gene Therapy / Novel Therapeutics (17%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 17 | 33% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 9:42 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Bolivian hemorrhagic fever
Disease patterns and progression
11 |
21% |
New treatment approaches | 9 | 17% |
Research summaries | 5 | 10% |
Patient case studies | 5 | 10% |
Testing and diagnosis research | 3 | 6% |
Other research | 1 | 2% |
Clinical study results | 1 | 2% |
Erickson R (2026). [PMID: 42042791](https://pubmed.ncbi.nlm.nih.gov/42042791/). *Vaccines (Basel)*. [Basic Science / Preclinical]
Monticelli SR (2026). [PMID: 41902296](https://pubmed.ncbi.nlm.nih.gov/41902296/). *Viruses*. [Basic Science / Preclinical]
Sharmin S (2026). [PMID: 41640223](https://pubmed.ncbi.nlm.nih.gov/41640223/). *Reviews in medical virology*. [Review / Meta-Analysis]
Clark JJ (2026). [PMID: 41513540](https://pubmed.ncbi.nlm.nih.gov/41513540/). *EBioMedicine*. [Basic Science / Preclinical]
Kapitonova MA (2026). [PMID: 41525354](https://pubmed.ncbi.nlm.nih.gov/41525354/). *PloS one*. [Basic Science / Preclinical]
Farhat I (2026). [PMID: 41539568](https://pubmed.ncbi.nlm.nih.gov/41539568/). *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. [Case Report / Case Series]
Alamri A (2026). [PMID: 40665184](https://pubmed.ncbi.nlm.nih.gov/40665184/). *Molecular diversity*. [Gene Therapy / Novel Therapeutics]
Seye S (2026). [PMID: 42069546](https://pubmed.ncbi.nlm.nih.gov/42069546/). *BMC Infect Dis*. [Epidemiology / Natural History]
Marandino A (2025). [PMID: 40872303](https://pubmed.ncbi.nlm.nih.gov/40872303/). *Pathogens (Basel, Switzerland)*. [Case Report / Case Series]
Tomatis C (2025). [PMID: 40514553](https://pubmed.ncbi.nlm.nih.gov/40514553/). *Current microbiology*. [Gene Therapy / Novel Therapeutics]
AI-curated news mentioning Bolivian hemorrhagic fever
Updated Jul 8, 2026
A new treatment for children aged 2 or older with sickle cell disease has been approved by the U.S. Food & Drug Administration. In a press release on Wednesday, the FDA announced it had approved Casgevy, the first gene therapy for children with sickle cell disease. (NewsNation) — A new treatment for children aged 2 or older with sickle cell disease has been approved by the Food & Drug Administration (FDA). In a Wednesday news release, the FDA announced it had approved Casgevy, the first gene therapy for children with the disease. “Casgevy is a gene therapy consisting of the patient’s own (autologous) hematopoietic (blood) stem cells, administered as a one-time single dose for intravenous infusion,” the release noted. “Pediatric patients as young as 2 years of age can now access a critical additional treatment option to treat these debilitating, life-threatening diseases,” Karim Mikhail, the acting director of the Center for Biologics Evaluation and Research, wrote. “These disorders carry a heavy burden for children and their families, affecting growth, development, and long-term health in profound ways,” Megha Kaushal, acting deputy director of the Office of Therapeutic Products in CBER, said in the release.